Drug Approval | November 21, 2022
Aurobindo Pharma receives 10 observations for Unit IX
The company had responded to the agency and carried out the required corrective actions.
The company had responded to the agency and carried out the required corrective actions.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has responded to the warning letter and carried out the committed corrections.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Subscribe To Our Newsletter & Stay Updated
